MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplan… Read more
MoonLake Immunotherapeutics (MLTX) - Total Assets
Latest total assets as of December 2025: $424.43 Million USD
Based on the latest financial reports, MoonLake Immunotherapeutics (MLTX) holds total assets worth $424.43 Million USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
MoonLake Immunotherapeutics - Total Assets Trend (2020–2025)
This chart illustrates how MoonLake Immunotherapeutics’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
MoonLake Immunotherapeutics - Asset Composition Analysis
Current Asset Composition (December 2025)
MoonLake Immunotherapeutics's total assets of $424.43 Million consist of 99.4% current assets and 0.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 78.8% |
| Accounts Receivable | $4.87 Million | 1.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how MoonLake Immunotherapeutics's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: MoonLake Immunotherapeutics's current assets represent 99.4% of total assets in 2025, an increase from 1.4% in 2020.
- Cash Position: Cash and equivalents constituted 78.8% of total assets in 2025, up from 1.2% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 1.2% of total assets.
MoonLake Immunotherapeutics Competitors by Total Assets
Key competitors of MoonLake Immunotherapeutics based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
MoonLake Immunotherapeutics - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - MoonLake Immunotherapeutics generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - MoonLake Immunotherapeutics is currently not profitable relative to its asset base.
MoonLake Immunotherapeutics - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.27 | 21.11 | 24.33 |
| Quick Ratio | 9.27 | 21.11 | 24.33 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $376.22 Million | $ 451.82 Million | $ 1.40 Million |
MoonLake Immunotherapeutics - Advanced Valuation Insights
This section examines the relationship between MoonLake Immunotherapeutics's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.28 |
| Latest Market Cap to Assets Ratio | 1.40 |
| Asset Growth Rate (YoY) | -11.2% |
| Total Assets | $424.43 Million |
| Market Capitalization | $594.94 Million USD |
Valuation Analysis
Above Book Valuation: The market values MoonLake Immunotherapeutics's assets above their book value (1.40 x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: MoonLake Immunotherapeutics's assets decreased by 11.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for MoonLake Immunotherapeutics (2020–2025)
The table below shows the annual total assets of MoonLake Immunotherapeutics from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $424.43 Million | -11.19% |
| 2024-12-31 | $477.93 Million | -9.23% |
| 2023-12-31 | $526.54 Million | +585.21% |
| 2022-12-31 | $76.84 Million | +693.63% |
| 2021-12-31 | $9.68 Million | -91.70% |
| 2020-12-31 | $116.63 Million | -- |